Business, energy, technology, markets and global industry news from Business News Today

KONFIDENT-KID

PharmaDeviceNews KONFIDENT-KID
Pharma & Biotech

Will pediatric KONFIDENT-KID data accelerate KalVista’s sebetralstat approval in hereditary angioedema?

KalVista's sebetralstat pediatric trial data heads to Madrid. What it means for the HAE on-demand market and a 2026 FDA filing. Read the analysis.

Read More
Pharma & Biotech

Can KalVista’s refill-led EKTERLY growth signal a new standard in on-demand HAE care?

KalVista’s oral HAE drug EKTERLY hit $49M in 2025 sales. Discover what strong refill demand and global expansion mean for rare disease treatment models.

Read More